Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
• Lucentis DME approval
• Xalatan new indication
• Inlay treats presbyopia
• Novel uveitis therapy
• Reducing SED


Survey

Is CME accreditation important to you?
Click here to vote

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.

Click here to contact Neil Hanley, sales manager.
November 03, 2010
Lucentis receives DME approval in EU
Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME). More...
Xalatan receives paediatric indication in Europe
Pfizer has announced that Xalatan (latanoprost) has been approved by the European Commission for the reduction of elevated IOP in the treatment of paediatric patients. The company has now applied for a patent extension in light of the approval. More...
Corneal inlay effectively treats presbyopia
The ACI 7000 corneal inlay has shown safety and efficacy over a two-year study period in presbyopia patients, according to a study published in the Journal of Refractive Surgery. More...
Product Profiles
Carl Zeiss Meditec
IOLMaster® 500 - With automatic and non-contact measurement of the patient's eye, the new IOLMaster 500 offers the fastest and easiest way of calculating the right IOL for each patient.

Read more...
 
Uveitis treatment shows promise
Curcumin-based treatment Norflo, has been shown to alleviate the symptoms of anterior uveitis in a recent study published in Clinical Ophthalmology, indicating a potential role for the anti-inflammatory treatment curcumin in eye inflammatory and degenerative conditions. More...
Reducing sensory eye dominance with learning protocol
A recent study revealed a novel push-pull training protocol that was designed to reduce sensory eye dominance (SED), which is mainly caused by unbalanced interocular inhibition. More...

 

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other
opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail
at Advanstar Communications Inc., Advanstar House, Park West, Sealand Road, Chester, CH1 4RN United Kingdom